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Abstract: The synthesis of four cymantrene-5-fluorouracil derivatives (1–4) and two cymantrene-adenine
derivatives (5 and 6) is reported. All of the compounds were characterized by spectroscopic methods
and the crystal structure of two derivatives (1 and 6), together with the previously described
cymantrene-adenine compound C was determined by X-ray crystallography. While the compounds
1 and 6 crystallized in the triclinic P-1 space group, compound C crystallized in the monoclinic
P21/m space group. The newly synthesized compounds 1–6 were tested together with the two
previously described cymantrene derivatives B and C for their in vitro antiproliferative activity
against seven cancer cell lines (MCF-7, MCF-7/DX, MDA-MB-231, SKOV-3, A549, HepG2m and
U-87-MG), five bacterial strains Staphylococcus aureus (methicillin-sensitive, methicillin-resistant and
vancomycin-intermediate strains), Staphylococcus epidermidis, and Escherichia coli, including clinical
isolates of S. aureus and S. epidermidis, as well as against the protozoan parasite Trypanosoma brucei.
The most cytotoxic compounds were derivatives 2 and C for A549 and SKOV-3 cancer cell lines,
respectively, with 50% growth inhibition (IC50) values of about 7 µM. The anticancer activity of the
cymantrene compounds was determined to be due to their ability to induce oxidative stress and to
trigger apoptosis and autophagy in cancer cells. Three derivatives (1, 4 and 5) displayed promising
antitrypanosomal activity, with GI50 values in the low micromolar range (3–4 µM). The introduction
of the 5-fluorouracil moiety in 1 enhanced the trypanocidal activity when compared to the activity
previously reported for the corresponding uracil derivative. The antibacterial activity of cymantrene
compounds 1 and C was within the range of 8–64 µg/mL and seemed to be the result of induced
cell shrinking.
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1. Introduction
Over the last years, organometallic compounds have been studied with respect to various
biological applications [1–4]. The majority of them are related to anticancer therapy [5–8], while less
attention has been devoted to organometallics as antibacterial [9,10] and antiparasite agents [11,12].
Cymantrene (tricarbonyl(η5-cyclopentadienyl)manganese; CymH) is a half-sandwich organometallic
compound that is stable in air and water [13]. The cymantrene molecule can be functionalized at
the η5-cyclopentadienyl ligand [14–16], and at the tricarbonyl ligand position [17,18]. This structural
diversity of the cymantrene molecule is the reason for its wide applicability in synthetic chemistry [19–21].
Recently, cymantrene derivatives have attracted considerable interest as biologically active agents.
For example, they have been reported as markers in immunoassays [22] and as intermediates in
the synthesis of organometallic steroid derivatives [23], and the cymantrenyl group has been used
for tamoxifen modification [24]. Furthermore, it has been shown that conjugation of cymantrene
to cell-penetrating peptides or proteins significantly increase their cytotoxic effect against cancer
cells [25–27].
Another field, where cymantrene derivatives have been studied, comprises the development
of antibacterial and antiparasite agents [28–33]. For instance, hetero-tri-organometallic compounds
containing the cymantrene moiety showed significant activity against methicillin-resistant Staphylococcus
aureus (MRSA) strain [30]. Furthermore, cymantrene derivatives of the antibiotic platensimycin were
reported [31]. In addition, cymantrene 4-aminoquinoline derivatives have been investigated for activity
against the malaria parasite Plasmodium falciparum, the sleeping sickness parasite Trypanosoma brucei,
and the Chagas disease parasite Trypanosoma cruzi [32]. Moreover, antitrypanosomal activity was also
reported for cymantrene triazole derivatives [33].
The above-mentioned examples support the development of new cymantrene-based compounds
with anticancer, antibacterial and antiparasite activity. Of particular importance is the new class
of cymantrene-nucleobase conjugates, recently reported by us [14]. Interestingly enough, some of
these molecules showed activity against bloodstream forms of T. brucei in the micromolar range.
In continuation and extension of our long-standing program in the field of bioorganometallic
chemistry [34–37], we describe here the synthesis and biological activity of six new cymantrene-nucleobase
(nucleobase = 5-fluorouracil or adenine) conjugates, together with the crystal structures of three of the
compounds. The main goal of the work was to evaluate the compounds against a broad range of
biological targets. The compounds were investigated for their antiproliferative activity (i) against
a panel of human cancer cells; (ii) against the protozoan parasite T. brucei; and (iii) Gram-positive
and Gram-negative bacteria strains. Moreover, for most of the compounds with anticancer activity,
additional biological assays were conducted in order to elucidate their molecular mechanisms of action.
2. Results and Discussion
2.1. Synthesis of Compounds 1–7
The compounds synthesized during this work can be divided into two groups. The first group
includes the cymantrene-5-fluorouracil derivatives 1–4, while the second group comprises the
cymantrene-adenine derivatives 5 and 6. This selection was justified by previous results, showing that
some ferrocene-5-fluorouracil and cymantrene-adenine conjugates displayed activity against S. aureus
(MRSA) and T. brucei pathogens, respectively [14,36]. The synthetic approach for the preparation of
1–4 is shown in Scheme 1, whereas the synthesis of 5 and 6 is depicted in Scheme 2.
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In general, the synthesis exploited methodologies developed recently in our laboratory for 
ferrocene, ruthenocene, and [2.2] paracyclophane nucleobase derivatives [36,37]. In a first step, 
3-chloropropionylocymantrene A [14] reacted with 5-fluorouracil to afford ketone 1 in 67% yield.  
In a second step, the carbonyl group in 1 was reduced with sodium tetrahydridoborate to afford 
alcohol 2 in 85% yield. 
 
Scheme 2. Synthesis of cymantrene-adenine derivatives 5 and 6. 
To obtain the products 3 and 5, the photochemical substitution reaction of the carbonyl ligand 
in alcohol 2 (Scheme 1) or alcohol B (Scheme 2) by the triphenylphosphine was utilized. Accordingly, 
compounds 3 and 5 were obtained in 47% and 43% yields, respectively. The subsequent treatment of 
the alcohols 2 and B with sodium hydride and methyl iodide allowed for obtaining the methylated 
compounds 4 and 6 in 40% and 79% yields, respectively. For assessing the biological activity of the 
newly obtained compounds, the propionylocymantrene 7 was also synthesized through Friedel-Crafts 
reaction and was fully characterized (Figure S4 and Scheme S1 in the SI). 
The compounds 1, 2, and 7 are yellow solids, the complexes 3 and 5 are green solids, and 
compound 6 is a colorless solid, while compound 4 is a yellow oil. The entire series of compounds is 
air-stable and can be stored in the fridge for months without signs of decomposition. The products 
were characterized by 1H-NMR, 13C-NMR, IR, mass spectrometry (MS), and elemental analysis. 
2.2. X-ray Crystal Structures of 1, 6 and C 
Single-crystals of 1, 6, and C suitable for X-ray diffraction analysis were crystallized by slow 
diffusion of pentane into chloroform solutions of 1, 6, and C. The molecular diagrams of the 
molecules 1, 6, and C, with the atom labelling schemes are shown in Figures 1–3 together with 
selected numerical values for bond lengths and valence angles. Crystal and structure refinement 
details are given in Table S1. The bond lengths and valence angles are summarized in Tables S2–S7. 
Compounds 1 and 6 crystallized in the triclinic P-1 space group, while compound C crystallized in 
the monoclinic P21/n space group. In the crystal lattice of 1, two independent molecules (1A and 1B) 
were observed. The compound C crystallizes as a solvate with two chloroform molecules in the 
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In general, the synthesis exploited methodologies developed recently in our laboratory for
ferrocene, ruthenocene, and [2.2] paracyclophane nucleobase derivatives [36,37]. In a first step,
3-chloropropionylocymantrene A [14] reacted with 5-fluorouracil to afford ketone 1 in 67% yield. In a
second step, the carbonyl group in 1 was reduced with sodium tetrahydridoborate to afford alcohol 2
in 85% yield.
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To obtain the products 3 and 5, the photochemical substitution re ction of the carbon l
ligand i alcohol 2 (Scheme 1) or alcohol B (Scheme 2) by the triphenylpho phine was utilized.
According y, compounds 3 and 5 were obtaine in 47% an 43% yields, respectively. T subsequent
treatment of the alcohols 2 and B with so ium hydr d and methyl iodide allowed for obta ning
meth lated compounds 4 and 6 in 40% and 79% yields, re pectively. For assessing the biological
activity of the newly obtained compounds, the propionylocymantren 7 was also synthesized through
Friedel-Crafts reaction and was fully characterized (Figure S4 and Scheme S1 in the SI).
The compounds 1, 2, an 7 are yellow solids, the complexes 3 a d 5 a e green solids, and
compound 6 is colorless solid, while compound 4 is a yellow oil. The entire series of compounds i
air-stable nd can be stored in the fridge for months with ut signs of decomposition. The products
were characterized by 1H-NMR, 13C-NMR, IR, mass spectrometry (MS), and elemental analysis.
2.2. X-ray Crystal Structures of 1, 6 and C
Single-crystals of 1, 6, and C suitable for X-ray diffraction analysis were crystallized by slow
diffusion of pentane into chlorofor solutions of 1, 6, and C. The molecular diagrams of the
molecules 1, 6, and C, with the atom labelling schemes are shown in Figures 1–3 together with
selected numerical values for bond lengths and valence angles. Crystal and structure refinement
details are given in Table S1. The bond lengths and valence angles are summarized in Tables S2–S7.
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Compounds 1 and 6 crystallized in the triclinic P-1 space group, while compound C crystallized in the
monoclinic P21/n space group. In the crystal lattice of 1, two independent molecules (1A and 1B) were
observed. The compound C crystallizes as a solvate with two chloroform molecules in the asymmetric
part of the unit cell. The molecular drawing of the solvate is provided in Figure S10. The X-ray
crystal structure analysis of compounds 1, 6, and C confirmed that the cymantrenyl moiety had a
three-legged piano-stool structure. The distance between the Mn-atom and the midpoint (Mp1) of the
cyclopentadienyl ring was 1.771(2) Å for 1A and 6, 1.770(2) Å for 1B and 1.767(2) Å for C. These values
are close to that of 1.764(3) Å reported previously for compound B [14].
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The differences in the corresponding geometrical parameters of 1A and 1B were small and they 
were related to the slightly altered orientation of the 5-fluorouracil group relative to the cymantrenyl 
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moiety was directed toward the oxygen atom of one of the carbonyl ligands. The distance between 
the calculated 5-fluorouracil ring midpoint (Mp2) and the O3A atom in 1A was 3.040(3)Å, while the 
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Mp1 corresponds to the midpoint of the cyclopentadienyl ring. Hydrogen atoms have been omitted
for clarity. Only molecule 1A is shown. Selected bond lengths [Å] and angles [◦]: Mn1(A)-C1(A),
1.822(4); Mn1(A)-C2(A), 1.803(4); Mn1(A)-C3(A), 1.796(3); Mn1(A)-C4(A), 2.131(3); O1(A)-C1(A),
1.126(5); O2(A)-C2(A), 1.147(5); O3(A)-C3(A), 1.150(4); C4(A)-C9(A), 1.472(4); C9(A)-O4(A), 1.220(4);
C10(A)-C11(A), 1.532(4); N1(A)-C12(A), 1.369(3); C13(A)-O6(A), 1.222(4); C13(A)-N2(A), 1.385(3);
C14(A)-F1(A), 1.352(3); C5(A)-C4(A)-C9(A)-O4(A); −7.4(5); and, N1(A)-C12(A)-N2(A)-C13(A), 6.9(4).
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moiety. In both of th molecules, the plane of the 5-fluorouracil moiety was almost perpendicular
relative to the plane of the cyclopentadienyl ring. A dihedral a gle between the above-mentioned
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fragments in 1A and 1B was 97.40(2)◦ and 87.61(2)◦, respectively. In both molecules, the 5-fluorouracil
moiety was directed toward the oxygen atom of one of the carbonyl ligands. The distance between
the calculated 5-fluorouracil ring midpoint (Mp2) and the O3A atom in 1A was 3.040(3)Å, while the
corresponding distance in the conformer 1B was 3.138(3)Å, respectively. In the case of compound
C, the X-ray diffraction analysis confirmed that the 1,2-bis(diphenylphosphino)ethane ligand (dppe)
binds to the Mn-atom in a chelate fashion. The plane of the adenine moiety was almost perpendicular
to the plane of the cyclopentadienyl group. The angle between these two planes was 90.73(11)◦. In the
solid state, individual molecules of compound C were stabilized by intramolecular C35–H35···O2
(2.740(4)Å) hydrogen bond. Furthermore, there also were C31–H31···pi-electron interactions between a
proton on the cyclopentadienyl ring and one of the phenyl rings in the dppe ligand.
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Figure 3. The molecular diagram of C with atomic displacement ellipsoids at the 50% probability level;
Mp1 corresponds to mid-point of the cyclopentadienyl ring. Hydrogen atoms and solvent molecules
have been omitted for clarity. Selected bond lengths [Å] and angles [◦]: Mn1-C1, 1.760(3); Mn1-P1,
2.199(1); Mn1-P2, 2.193(1); O1-C1, 1.169(4); P2-C3, 1.862(3); P1-C2, 1.854(3); C2-C3, 1.540(4); C28-C33,
1.502(4); C33-O2, 1.417(4); C34-C35, 1.516(4); N1-C36, 1.356(4); N2-C37, 1.379(4); N5-C38, 1.327(4);
P1-C2-C3-P2, −40.0(3); C29-C30-C31-C32, 0.3(4); N1-C36-N2-C37, 0.1(4); and, N3-C39-N4-C40, 0.0(7).
2.3. Determination of log Po/w
Lipophilicity is an important parameter in the context of biological activity studies and can be
expressed by the octanol/water partition coefficient (log Po/w). In this study, a chromatographic method
and the Soczewin´ski–Wachtmeister relationship were used in order to determine the lipophilicity of
the compounds [38–41] (Table 1). All of the tested compounds showed a good linear correlation with
high coefficients of determination (R2) (Table S8). The partition coefficients of the compounds were
within the range of 2.6–5.7. Thus, all of them showed some degree of lipophilicity. The derivative C
with the dppe ligand was the most lipophilic compounds (log Po/w = 5.7), while compounds 1 and B
were the least lipophilic agents (both log Po/w = 2.6). Since the difference in the partition coefficient of
these compounds is greater than three logs, quite different cellular accumulation of these molecules
can be expected. In turn, the compound Cym H and derivatives 4 and 6 should have similar cellular
accumulation patterns as their log Po/w had the same value (3.5). However, it should be pointed out
that lipophilicity is not the sole factor that determines the uptake and distribution of molecules in cells.
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Table 1. Lipophilicity (log Po/w) and cytotoxicity (IC50; µM) of compounds CymH, 1–7, B, and C against human cancer cells a.
Compound Log Po/w SKOV-3 MCF-7 MCF-7/DX MDA-MB-231 A549 HepG2 U87-MG
CymH 3.5 121 ± 3.05 86.01 ± 1.30 143.55 ± 2.24 68.60 ± 1.74 87.05 ± 1.35 74.66 ± 3.73 84.44 ± 4.22
1 2.6 75.14 ± 3.76 70.48 ± 2.52 137.49 ± 3.41 27.86 ± 1.11 25.05 ± 1.25 114.45 ± 2.72 64.47 ± 3.22
2 2.8 97.48 ± 2.87 119.45 ± 2.97 nd * >150 7.24± 0.34 >150 100.29 ± 1.01
3 5.2 53.01 ± 2.65 57.78± 2.89 39.92± 1.41 35.73 ± 1.44 20.35 ± 1.09 65.76 ± 3.29 24.89 ± 1.24
4 3.5 >150 >150 nd >150 >150 >150 >150
5 4.8 63.83 ± 3.19 102.16 ± 1.11 nd 55.95 ± 2.07 23.72 ± 0.86 106.23 ± 2.31 54.19 ± 2.71
6 3.5 77.1 ± 3.86 111.34 ± 3.57 nd >150 101.51 ± 1.08 86.89 ± 2.34 130.61 ± 3.53
7 3.2 69.84 ± 3.49 >150 nd 63.01 ± 1.32 30.61 ± 1.35 109.57 ± 2.48 83.62 ± 1.18
B 2.6 >150 >150 nd >150 >150 >150 >150
C 5.7 7.11± 0.36 103.74 ± 1.19 nd 43.07 ± 1.95 16.47 ± 0.82 66.59 ± 3.33 38.26 ± 1.91
DOX nd 0.858 ± 0.044 0.439± 0.026 48.50± 2.78 1.073 ± 0.062 0.300 ± 0.018 0.569 ± 0.021 0.610 ± 0.029
a SKOV-3 (ovarian adenocarcinoma), MCF-7 (hormone-responsive breast adenocarcinoma), MCF-7/DX (estrogen-responsive breast adenocarcinoma resistant to doxorubicin), MDA-MB-231
(triple negative breast adenocarcinoma), A549 (non-small cell lung carcinoma), HepG2 (hepatocellular carcinoma) and U87-MG (glioblastoma). The cells were incubated for 24 h with
cymantrene compounds (cytotoxic effect). Results are expressed as means ± SEM of at least three independent experiments in six repeats each. In MCF-7/DX cells only the cytotoxicity of
cymantrenes showing IC50 < 100 µM) in the parental MCF-7 cell line was estimated. nd—not determined. Cytotoxicity of cymantrene compounds showing IC50 > 100 µM in the parental
MCF-7 cell line was not determined.
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3. Biological Studies
The newly synthesized compounds 1–6 were tested for their anticancer, antitrypanosomal, and
antibacterial activities. For comparison, the nucleobase-free compound 7 and the previously studied
cymantrene-adenine compound C (Figure 4) [14] were also investigated.
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3.1. Evaluation of Anticancer Activity 
Anticancer activity of cymantrenes was determined using a panel of human cancer cell lines 
that were derived from solid tumors. These included cell lines of estrogen-responsive, doxorubicin 
resistant, and triple negative breast adenocarcinomas (MCF-7, MCF-7/DX, and MDA-MB-231), ovarian 
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and glioblastoma (U-87 MG). The inhibitory effect of cymantrene derivatives on cell proliferation and 
growth was determined based on survival curves and was expressed as IC50 values (concentration 
required to achieve a 50% decrease in cell viability when compared to the viability of untreated 
control cells) calculated using GraphPad Prism 4.02 software for Windows (GraphPad Software,  
San Diego, CA, USA). Cell viability was determined by the MTT microplate spectrophotometric 
cytotoxicity test. 
Most compounds showed a dose-dependent effect on the growth of the cancer cell lines 
assayed (Figure S11A,B), with most IC50 value in the mid micromolar range (Table 1). The most 
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Interestingly, the replacement of a CO group in 2 with a triphenylphosphine group in 3 increased 
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effect, which reduced activity upon reduction of a keto function to a hydroxyl function, was 
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derivative of B, compound 6, displayed increased cytotoxic activity against most of the cancer cell lines 
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values, indicating the importance of molecule lipophilicity for the biological activity of 
cymantrene-nucleobase conjugates. Interesting is also the finding that the unsubstituted cymantrene 
(CymH) and the propionyl-substituted cymantrene (7), which both are precursor molecules for the 
cymantrene nucleobase conjugates, were moderately cytotoxic (Table 1). This shows that the source 
molecules inherently have cytotoxic properties. Other intriguing observations were that the 
doxorubicin-resistant MCF-7/DX cell line was more sensitive to compound 3 than its DOX-sensitive 
counterpart cell line MCF-7. At the same time, an anticancer drug doxorubicin (DOX), which is 
routinely employed in clinical oncology and was used in our study as a reference, was almost 
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cells. Moreover, the triple negative MDA-MB-231 cell line was also more sensitive to the most of the
evaluated cymantrene derivatives than the hormone-dependent MCF-7 cell line, which is the advantage
of the tested compounds. In this respect, one has to remember that new strategies in the treatment of
triple-negative breast cancer, which is one of the most refractory cancer to conventional chemotherapy,
are highly required [42]. Our results show that under the same conditions, the reference drug DOX was
about twofold less effective against MDA-MB-231 cells than against MCF-7 cells. Among investigated
cancer cell lines, non-small lung adenocarcinoma cells A549 were the most sensitive to the majority of
the investigated compounds.
3.2. Determination of Cytotoxic Mechanism of Action
To get a deeper insight into the molecular mechanisms that are underlying the anticancer activity
of the studied cymantrenes, we investigated their ability to generate oxidative stress (OS) and evaluated
the type of cell death that was triggered in treated cancer cells. Experiments were performed with the
ovarian adenocarcinoma SKOV-3 cells because this cell line was the most sensitive to the overall most
active compound, the adenine conjugate C.
3.2.1. Induction of Apoptosis and Autophagy
To determine the mode of cell death that was triggered by cymantrene derivatives, appropriately
stained SKOV-3 cells were evaluated for morphological changes using fluorescence microscopy.
For evaluation of apoptosis and autophagy, cells were stained with Hoechst 33258/propidium iodide
to distinguish between live, apoptotic and necrotic cells and reveal condensed chromatin and apoptotic
bodies (a hallmark of apoptosis), and with acridine orange to detect the development of acidic vesicular
organelles (AVOs—a hallmark of autophagy). All cymantrene derivatives mainly induced apoptosis
and autophagy (representative examples of these processes are shown in Figure 5, and a full panel of
pictures is shown in Figure S12A–C).
Numerous morphological changes typical for apoptosis can be identified in cells that are
treated with cymantrene compounds: shrunk cells with picnotic nuclei and highly condensed and
fragmented chromatin (karyorrhexis), cells with marginalization of chromatin, cells with plasma
membrane protrusions (“blebs”), cells with apoptotic bodies, and cells with cytoplasmic bridges
between them (Figure 5 and Figure S12A–C). Moreover, cells treated with some of the compounds,
e.g., compound 3, showed features of mitotic cell death, such as the presence of giant and polyploid
cells. These observations suggest that induction of apoptosis and possibly mitotic catastrophe could
be important mechanisms of the cytotoxic action of cymantrene compounds. However, the different
cymantrene derivatives differed in their effectiveness to induce apoptosis in SKOV-3 cells. Time course
experiments revealed that, when compared to untreated control cells, cymantrene compounds 3, 4,
and B caused the smallest change (only a three-fold increase of apoptotic cells), while the remaining
derivatives produced substantially larger alterations (6-fold (1, 6), 9-fold (5, 7, C), and 11-fold (2)
increase of apoptotic cells) (Figure 6).
While the increase of the apoptotic cell fraction after incubation with compounds 5 and C was
predominantly related to early apoptotic cells, treatment with compounds 2 and 7 resulted in a rise in
the late-apoptotic cell fraction (Figure 6). Bearing in mind that compounds 4 and B did not display any
cytotoxic activity (IC50 > 150 µM), their poor capacity to induce aspoptosis is therefore not surprising.
However, that compound 3, which was the second most cytotoxic cymantrene against SKOV-3 cells,
showed only weak apoptotic activity comparable to that of the non-cytotoxic compounds 4 and B was
unexpected. Nevertheless, it should be pointed out that compound 3 induced extensive mitotic cell
death (Figure 5 and Figure S12A–C) that might be responsible for the observed cytotoxic activity of
this derivative. At the end of the time course experiment (48 h post-treatment time point), an increase
in the fractions of late apoptotic and necrotic cells was noted for all of the compounds (Figure 6).
This suggests that some of the damaged apoptotic cells, in particular those treated with compounds
2, 5, and 7, underwent secondary necrosis, contributing to the increase in the necrotic cell fraction.
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However, necrosis accounted only to a lesser extent to the cytotoxic action of the compounds, which is
desirable, as this would reduce the risk of triggering inflammatory processes in neighboring tissue [43].
Molecules 2017, 22, 2220 10 of 25 
 
of the compounds, which is desirable, as this would reduce the risk of triggering inflammatory processes 
in neighboring tissue [43]. 
 
Figure 5. Example enlarged photomicrographs illustrating induction of apoptosis, autophagy and 
mitotic catastrophe in human ovarian adenocarcinoma cells SKOV-3 by cymantrene derivatives 1, 2, 
3, 7, B, and C and their core precursor CymH. The cells were stained with acridine orange (AO) and 
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analyzed with an inverted fluorescence microscope (Olympus IX70, Tokyo, Japan) at 400× 
magnification, except cells stained with AO, which were photographed under 150× magnification. The 
images marked with arrows show the most typical morphological changes associated with different 
type of cell death induced by cymantrene compounds during 24 h-treatment and following culture of 
SKOV-3 cells in drug-free medium for 24 or 48 h (0 h—cells examined immediately after the 
treatment): (a) pale-blue live cells; (b) intense bright-blue early apoptotic shrunk cells with pycnotic 
nucleus; (c) violet late apoptotic cells; (d) cells with highly condensed and fragmented chromatin 
(karyorrhexis); (e) marginalization of chromatin; (f) cells with plasma membrane protrusions 
(“blebs”); (g) apoptotic bodies; (h) cytoplasmic bridges between the cells. Presence of giant cells (i), 
polyploid cells with two nuclei (j) and cells with AVOs (k) suggest concomitant mitotic catastrophe 
and autophagy, respectively. 
In addition to apoptosis and mitotic cell death, the process of autophagy was also observed in 
SKOV-3 cell upon treatment with cymantrene compounds (Figures 5 and S12A–C). Time course 
experiments showed a significant increase in cells containing AVOs (Figure 7).  
  
Figure 5. Example enlarged photomicrographs illustrating induction of apoptosis, autophagy and
itotic catastrophe in human ovarian adenocarcinoma cells SKOV-3 by cymantrene derivatives 1,
2, 3, 7, B, and C and their core precursor CymH. The cells were stained with acridine orange (AO)
and double-stained with fluorescence dyes Hoechst 33258 (Ho33258) and propidium iodide (PI) and
then analyzed with an inverted fluorescence microscope (Olympus IX70, Tokyo, Japan) at 400
agnification, except cells staine ith , hich ere photographed under 150 agnification. he
i a es ar ed it arr s s t e st t ical r l ical c a es ass ciate it iffere t
t e f cell e t i ce c tre e c s ri -tre t e t f ll i c lt re f
- cells in drug-free medium for 24 or 8 h (0 h—cells examined immediately after the treatment):
(a) pal -blue live cells; (b) int nse right-blue early apoptotic shrunk ells with pycnotic nucleus;
(c) violet late apoptotic cells; (d) ells with highly condensed and fragm nted chromati (karyorrhexis);
e) ma ginalization of chromatin; (f) cells with plasma membrane protrusions (“blebs”); (g) apopt tic
bodies; (h) cytoplasm ri ges between the cells. Presence of giant cells (i), polyploid cells with two
nuclei (j) and cells wi h AVOs (k) suggest concomitant mitotic catastrophe and u ophagy, respectively.
In addition to apoptosis and mitotic cell death, the process of autophagy was also observed in
SKOV-3 cell upon treatment with cymantrene compounds (Figure 5 and Figure S12A–C). Time course
experiments showed a significant increase in cells containing AVOs (Figure 7).
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Figure 7. Induction of AVOs in SKOV-3 cells by cymantrene derivatives 1–7, B, C and CymH. The 
cells were incubated with IC50 concentrations of cymantrenes for 24 h under the same conditions as 
those applied in the cytotoxicity test and then examined immediately after the treatment (0 h time point) 
or cultured in drug-free medium for 24 or 48 h (24 h and 48 h time points, respectively). The time 
dependence of changes was statistically evaluated as described in Experimental Section (Section 4.5.2. 
Statistical Analysis). The fractions of AVOs containing cells at 24 h and 48 h time points were 
compared with corresponding fractions of AVOs containing cells at 0 h time point (* p < 0.05) and the 
fractions of AVOs containing cells at 48 h time point were compared with corresponding fractions of 
AVOs containing cells at 24 h time point (# p < 0.05). All of the changes in cells treated with cymantrenes 
were statistically significant in relation to untreated controls (for clarity not shown on the graph). 
Figure 6. Induction of apoptosis in human ovarian adenocarcinoma cells SKOV-3 by cymantrene
derivatives 1–7, B, C, and their core precursor CymH. Changes in the fraction of live, early apoptotic,
late apoptotic and necrotic fraction of SKOV-3 cells after 24 h treatment with IC50 conce trations of
cymantrenes and following post-treatment incubation in drug-f ee m dium for 24 and 48 h.
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Figure 7. Induction of AVOs in SKOV-3 cells by cymantrene derivatives 1–7, B, C and CymH. The cells
were incubated with IC50 concentrations of cymantrenes for 24 h under the same conditions as those
applied in the cytotoxicity test and then examined immediately after the treatment (0 h time point)
or cultured in drug-free medium for 24 or 48 h (24 h and 48 h time points, respectively). The time
dependence of changes was statistically evaluated as described in Experimental Section (Section 4.5.2.
Statistical Analysis). The fractions of AVOs containing cells at 24 h and 48 h time points were compared
with corresponding fractions of AVOs containing cells at 0 h time point (* p < 0.05) and the fractions
of AVOs containing cells at 48 h time point were compared with corresponding fractions of AVOs
containing cells at 24 h time point (# p < 0.05). All of the changes in cells treated with cymantrenes were
statistically significant in relation to untreated controls (for clarity not shown on the graph).
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The greatest autophagic changes were recorded with the compounds CymH, 2, 6, 7, and C
(Figure 7). Less induction of autophagy was observed with compounds 1, 4, 5, and B, while
very little autophagic activity was triggered by compound 3 (Figure 7). As the unsubstituted
cymantrene molecule was itself a strong inducer of autophagy in SKOV-3 cells, it can be suggested
that the cymantrene core of the nucleobase conjugates is probably the autophagy-inducing part
of the derivatives. These results indicate that autophagy could be another cytotoxic mechanism
of action of cymantrene nucleobase conjugates. The autophagic pathway of cell death has been
recently considered as a new important target mechanism that could be exploited to mitigate or to
overcome the resistance of tumor cells to chemotherapy-induced apoptosis [44]. Many studies have
shown that there is an interplay between apoptosis and autophagy, indicating that the induction
of apoptosis is often connected with an activation of autophagy [45]. Depending on the conditions,
autophagy may either result in tumor cell death or promote tumor cell survival. For example, following
physicochemical cell damages by radiation therapy or chemotherapy, an increased level of autophagy
improves the ability of tumor cells to repair the damage [46]. However, excessive autophagy in tumor
cells promotes autophagic cell death, resulting in an effective treatment of cancer [47]. Thus, induction
of autophagic cell death has been considered in recent times as an important cancer therapeutic strategy.
In this regard, the ability of cymantrene compounds to induce both apoptotic and non-apoptotic
(pro-death autophagy) death pathways in cancer cells should be seen as a great advantage of this class
of organometallics.
3.2.2. Induction of Oxidative Stress
Oxidative stress is a part of the cytotoxic activity of many anticancer agents and the production of
reactive oxygen species (ROS) is considered as one of the main molecular mechanisms accompanying
chemotherapy, radiotherapy, and photodynamic therapy [48–51]. Since ROS can act as both oxidants
and antioxidants, depending on the conditions, pro- and anti-oxidant therapies have been proposed for
the treatment of cancer. So far, both ROS scavenging and ROS boosting anticancer therapies have shown
promising results in vitro and in vivo [48]. Using an appropriate fluorescence probe, we measured the
amount of ROS in cancer cells that were treated with cymantrene derivatives. The results show that
production of ROS by cymantrene compounds in SKOV-3 cells is concentration and time dependent
(Figure 8). The greatest increase in ROS was observed after 30 min treatment, with the highest
concentration of cymantrene conjugates employed (2 × IC50) (Figure 8). Generally, the most cytotoxic
compounds 1, 3, 5, and C (Table 1) generated the largest amounts of ROS, although there was no direct
correlation between the IC50 concentration of a particular compound and the produced intracellular
ROS. For example, the most toxic compound for SKOV-3 cells, derivative C (IC50 = 7.11 µM), generated
a similar amount of ROS as the 10-fold less toxic compound 1 (IC50 = 75.14 µM). As compounds 1, 3, 5,
and C were effective in the production ROS, as well as in the induction of apoptosis and autophagy,
these processes might contribute together to the cytotoxic action of the molecules [52–54].
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Figure 8. Changes in the relative level of ROS in SKOV-3 cells treated for 0.5 or 3 h with different 
concentrations (0.5 × IC50, IC50, and 2 × IC50) of cymantrenes 1, 2, 3, 5, 6, 7, C, and CymH when compared 
with the ROS amount in untreated controls (100%). The kinetics of ROS formation was chased over 0–180 
min time period after the treatment. The results are the means ± SD of 3 independent experiments, 
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3.3. Evaluation of Antitrypanosomal Activity
The antitrypanocidal activity of cymamtrene derivatives 1–6 was determined with bloodstream
forms of the T. brucei variant 427-221a [55], while the general cytotoxicity of the compounds was
evaluated with human myeloid leukemia HL-60 cells [56], using the resazurin viability assay described
previously [57]. As we recently have shown that cymantrene-uracil derivatives inhibit the growth of
trypanosomes [14], we were now interested whether cymantrene conjugates containing 5-fluorouracil
as nucleobase would display improved antitrypanosomal activity. The rationale behind this approach
was that 5-fluorouracil is a chemotherapeutic drug and that antitumor agents are usually also
active against trypanosomes [58]. Indeed, the cymantrene-5-fluorouracil derivative 1 exhibited
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better trypanocidal activity, but also some enhanced cytotoxicity (Table 2) when compared to its
non-fluorinated counterpart tested previously (T. brucei: MIC = 100 µM, GI50 = 3.6 µM; HL-60:
MIC > 100 µM, GI50 > 100 µM [14]). Hence, the selectivity (ratio of cytotoxic to trypanocidal activity)
of compound 1 was not improved. The corresponding alcohol 2 of compound 1 was nontoxic to both
trypanosomes and HL-60 cells (Table 2).
Table 2. The in vitro antitrypanosomal and cytotoxic activity of CymH, compounds 1–6 and the
reference suramin against T. brucei and human myeloid leukemia HL-60 cells.
T. brucei HL-60 Selectivity
Compound MIC a (µM) GI50 b (µM) MIC (µM) GI50 (µM) MIC Ratio GI50 Ratio
CymH 100 44.6 ± 12.3 >100 >100 >1 >2.2
1 10 3.02 ± 0.14 100 33.1 ± 3.4 10 11.0
2 >100 >100 >100 >100 1 1
3 10 4.27 ± 0.13 100 30.6 ± 2.6 10 7.2
4 100 29.6 ± 6.8 >100 >100 >1 >3.4
5 10 3.14 ± 0.31 100 28.7 ± 3.0 10 9.1
6 100 26.1 ± 1.9 >100 95.2 ± 44.4 >1 3.6
B c >100 30.8 ± 3.5 >100 >100 1 >3.2
C c 10 1.67 ± 0.37 100 21.8 ± 8.6 10 13.1
DFMO d >125 23.9 n.d. n.d. n.d. n.d.
Suramin 0.1–1 0.039 ± 0.003 >100 >100 >1000–100 >2564
a MIC (minimum inhibitory concentration, i.e., the concentration of the compounds at which all cells were killed);
b GI50 (50% growth inhibition, i.e., the concentration of a compound necessary to reduce the growth rate of cells by
50% to that of controls); c Data from [14]; d Data from [59]; n.d. not determined.
To increase the lipophilicity of the alcohol 2, the compound was further modified to yield the
triphenylphosphine derivative 3 and the methylated derivative 4. Whereas, 3 displayed similar
antitrypanocidal and cytotoxic activities as compound 1, derivative 4 exhibited only fractionally
increased antitrypanosomal activity and no cytotoxic effect (Table 2). Since modification of compound 2
with either a triphenylphosphine ligand or methyl group resulted in derivatives with increased
trypanocidal activities, we were wondering whether this strategy would also help to improve the
antitrypanosomal activity of the cymantrene-adenine alcohol B. Derivative B was previously found
not to be a very active compound (T. brucei: MIC > 100 µM, GI50 = 30.8 µM; HL-60: MIC > 100 µM,
GI50 > 100 µM [14]). As expected, compounds 5 (triphenylphosphine derivative of B) showed increased
activity, while 6 (methylated derivative of B) displayed similar antitrypanocidal and cytotoxic activities
as compound 4 (Table 2). The most active compounds 1, 3, 5, and C were found to display trypanocidal
activity that were within the range of difluoromethylornithine (DFMO) and suramin (Table 2), two
drugs that are currently used to treat sleeping sickness. Although their MIC and GI50 ratios of cytotoxic
to trypanocidal activities were only in a moderate range of 7–13, one should bear in mind that a cancer
cell line was used for determining the selectivity. Therefore, when compared with non-malignant cells,
it is likely that the cytoxocity of the compounds are overestimated.
In general, the results showed that lipophilic phosphine ligands increase the trypanocidal activity
of the investigated compounds to a greater extent than methylation.
3.4. Evaluation of Antibacterial Activity
Organometallic compounds play an increasingly important role in the search for new antibacterial
agents [9,10,34]. We, therefore, thought to investigate also the bactericidal activity of the newly synthesized
cymantrenes 1–7, compound C and CymH. The antibacterial activity of the compounds was tested against
Gram-positive methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA),
vancomycin-intermediate S. aureus (VISA), S. epidermidis, and Gram-negative Escherichia coli bacterial
strains, and expressed as minimal inhibitory concentration (MIC) values (Table 3).
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Table 3. In vitro antibacterial activity of complexes 1–6, C, and the 7, CymH compounds against
reference bacterial strains (MIC µg/mL) a.
Compound
MIC (µg/mL)
S. aureus ATCC®
29213™ (MSSA)
S. aureus ATCC®
43300™ (MRSA)
S. aureus ATCC®
700787™ (VISA)
S. epidermidis
ATCC® 12228™
E. coli ATCC®
BAA-198™
C 32 32 32 16 >128
1 64 32 32 8 >512
2 >512 >512 >512 >512 >512
3 >256 >256 >256 >256 >256
4 >512 >512 >512 >512 >512
5 >256 >256 >256 >256 >256
6 >512 >512 >512 >512 >512
7 >512 >512 >512 >512 >512
CymH >512 >512 >512 >512 >512
penicillin G 2 16 32 2 >256
polymyxin B 256 256 >256 64 0.125
a MIC (the concentration of a compound necessary to reduce the growth of bacterial cells by 50% to that of controls)
value of the reference compound, penicillin G. against S. aureus ATCC® 29213 is 2 µg/mL.
The nucleobase-free compounds 7 and CymH were not active, whereas the derivatives 1 and
C exhibited remarkable potency against all of the Gram-positive bacterial strains, including MRSA
and VISA pathogens. None of the tested compounds showed any activity against the Gram-negative
E. coli strain. This lack of activity against E. coli can be probably explained by an impeded cellular
uptake of the compounds through the Gram-negative cell wall that consists of two layers and effective
protein efflux pump systems [60]. The antibacterial activities of 1 and C were further tested against
four clinical isolates of S. aureus and two clinical isolates of S. epidermidis (Table 4).
Table 4. In vitro antibacterial activity of complexes 1 and C compounds against clinical isolates
(MIC µg/mL) a.
Compound
MIC (µg/mL)
Clinical
S. aureus
(MSSA)
26/11
Clinical
S. aureus
(MSSA)
30/11
Clinical
S. aureus
(MRSA)
31/12
Clinical
S. aureus
(MRSA)
44/12
Clinical
S. epidermidis
(MSSA)
37/12
Clinical
S. epidermidis
(MSSA)
43/12
C 32 32 32 32 16 16
1 32 64 64 32 4 8
penicillin G 0.5 2 32 8 16 8
polymyxin B 256 256 256 256 128 64
a MIC (the concentration of a compound necessary to reduce the growth of bacterial cells by 50% to that of controls)
value of the reference compound, penicillin G against S. aureus ATCC® 29213 is 2 µg/mL.
Promisingly, the clinical isolates showed similar sensitivities for the two compounds as the
reference strains. However, the antibacterial activity of 1 and C cannot be simply explained on the
basis of their lipophilicity since their log Po/w values differ by three logs.
In order to elucidate the bactericidal mechanism of action of cymantrenes, the effect of compound
1 on the morphology of S. aureus ATCC 25923 was exemplary studied by scanning electron microscopy
(SEM) (Figure 9). Whereas, control samples exhibited the normal cellular morphology with smooth
cell surfaces (Figure 9(A1–A3)), bacteria after exposure to compound 1 at concentrations of 48 µg/mL
and 64 µg/mL (values between the MIC (32 µg/mL) and minimal bactericidal concentration;
MBC (128 µg/mL)) for 24 h showed severe morphological alterations in cell dimensions and structure,
as well as the disruption of the outer envelope (Figure 9(B1–B3) and (C1–C3)). At the highest
concentration tested (64 µg/mL), a complete destruction of the bacterial cell was observed in most
cases and, as a result, only bacterial debris appeared in the filters (Figure 9(C3)).
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4.2. Chemistry
Synthesis of Ketone 1. To a stirred solution of 3-chloropropionylcymantrene (294 mg, 1.0 mmol) in
DMF (20 mL), trimethylamine (278 µL 2.0 mmol) was added in a single portion at ambient temperature.
After 20 min of stirring, 5-fluorouracil (130 mg, 1.0 mmol) was added and the mixture was stirred at a
temperature of 75 ◦C for 5 h. Subsequently, the solvent was evaporated and the residue subjected to a
preliminary column chromatography on SiO2 (eluent chloroform:methanol 50:2 (v/v)), which afforded
1. Crude 1 was crystallized from a chloroform-n-pentane mixture affording the analytically pure 1.
1 Yellow solid, 67% (260 mg). 1H-NMR (600 MHz, DMSO-d6): δ = 11.74 (s, 1H, NH), 8.00 (d, JH,F = 6.6 Hz,
1H, H-6 5-fluorouracil), 5.81 (pt, JH,H = 2.4 Hz, 2H, Cp), 5.21 (pt, JH,H = 2.4 Hz, 2H, Cp), 3.90 (t,
JH,H = 6.6 Hz, 2H, CH2), 3.08 (t, JH,H = 6.6 Hz, 2H, CH2). 13C-NMR (150 MHz, DMSO-d6): δ = 223.4,
195.7, 157.4 (d, JC,F = 26 Hz), 149.4, 139.2 (d, JC,F = 228 Hz), 130.7 (d, JC,F = 33 Hz), 91.6, 87.5, 85.3, 43.4,
37.2. MS (EI, 70 eV): m/z = 304 (M+ − 3CO). FTIR (KBr): 3059 (CH), 2028 (CO), 1935 (CO), 1928 (CO),
1696 (C=O), 1680 (C=O), 1663 (C=O) cm−1. Anal. Calcd for C15H10N2O6FMn: C, 46.41%; H, 2.60%.
Found: C, 46.22%; H, 2.78%.
Synthesis of Alcohol 2. To a stirred THF solution (20 mL) containing 1 (194 mg, 0.5 mmol), NaBH4 (19 mg,
0.5 mmol) was added in a single portion at room temperature. After 20 min of stirring, the reaction
mixture was poured into 20 mL of water, extracted with chloroform, dried over MgSO4, and the
obtained solution was evaporated to dryness. The residue was subjected to column chromatography
on SiO2 (eluent chloroform:methanol 50:3 (v/v)). Crystallization from dichloromethane-n-pentane
afforded the analytically pure alcohol 2.
2 Yellow solid, 85% (165 mg).1H-NMR (600 MHz, DMSO-d6): δ = 11.70 (s, 1H, NH), 8.01 (d, JH,F = 7.2 Hz,
1H, H-6 5-fluorouracil), 5.43 (d, JH,H = 5.4 Hz, 1H, OH), 5.08 (m, 1H, Cp), 5.06 (m, 1H, Cp), 4.89 (m,
1H, Cp), 4.87 (m, 1H, Cp), 4.24 (m, 1H, CH), 3.82 (m, 1H, CH2), 3.67 (m, 1H, CH2), 1.92 (m, 1H, CH2),
1.78 (m, 1H, CH2). 13C-NMR (150 MHz, DMSO-d6): δ = 225.7, 157.6 (d, JC,F = 27 Hz), 149.6, 139.6
(d, JC,F = 228 Hz), 130.5 (d, JC,F = 33 Hz), 111.0, 83.1, 82.5, 82.2, 81.7, 63.9, 45.4, 36.8. MS (EI, 70 eV):
m/z = 306 (M+ − 3CO), 288 (M+ − 3CO − H2O). FTIR (KBr): ≈3500 (OH), 3167, 3050, 2835, 2015 (CO),
1932 (CO), 1682 (C=O), 1660 (C=O) cm−1. Anal. Calcd for C15H12N2O6FMn: C, 46.17%; H, 3.10%.
Found: C, 46.52%; H, 3.33%.
General Procedure for the Synthesis of Compounds 3 and 5. An anhydrous THF (40 mL) solution containing
either alcohol 2 (195 mg, 0.5 mmol) or B (198 mg, 0.5) and triphenylphosphine (131 mg, 0.5 mmol)
was photolysed with a 200 W high-pressure mercury lamp for 2 h. The solvent was evaporated to
dryness. The residue was subjected to column chromatography on SiO2 (eluent chloroform:methanol
50:1 (v/v)). Crystallization from chloroform/n-pentane gave the analytically pure triphenylphosphine
derivatives 3 and 5.
3 Green solid, 47% (147 mg). 1H-NMR (600 MHz, DMSO-d6): δ = 11.68 (s, 1H, NH), 7.98 (d,
JH,F = 6.6 Hz, 1H, H-6 5-fluorouracil), 7.449 and 7.439 (two overlapped s, 9H, Ph), 7.36 (m, 6H,
Ph), 5.20 (d, JH,H = 6.0 Hz, 1H, OH), 4.56 (pq, JH,H = 3.0 Hz, JH,H = 1.8 Hz, 2H, Cp), 4.22 (m, 1H, CH),
4.02 (pd, JH,H = 1.8 Hz, 2H, Cp), 3.83 (m, 1H, CH2), 3.68 (m, 1H, CH2), 1.96 (m, 1H, CH2), 1.82 (m,
1H, CH2). 13C-NMR (150 MHz, DMSO-d6): δ = 232.8 (d, JP,C = 21 Hz), 232.6 (d, JP,C = 18 Hz), 157.6,
149.5, 137.6 (d, JP,C = 40 Hz), 132.4 (d, JP,C = 10 Hz), 129.7, 128.4 (d, JP,C = 9 Hz), 106.4, 84.1, 82.6, 81.0,
79.6, 64.3, 45.5, 35.7. 31P{1H} NMR (243 MHz, DMSO-d6): δ=91.58. MS (EI, 70 eV): m/z = 624 (M+),
550 (M+ − 2CO − H2O). FTIR (KBr): ≈3500 (OH), 3072, 3053, 2961, 2923, 1926 (CO), 1856 (CO),
1692 (C=O), 1660 (C=O), 1477, 1429 cm−1. Anal. Calcd for C32H27N2O5FPMn + MeOH: C, 60.37%;
H, 4.76%. Found: C, 60.46%; H, 4.71%.
5 Green solid, 43% (135 mg). 1H-NMR (600 MHz, DMSO-d6): δ = 8.12 (s, 1H, H-2 adenine), 8.09 (s, 1H,
H-8 adenine), 4.429 and 7.421(two overlapped s, 9H, Ph),7.34 (m, 6H, Ph), 7.13 (s, 2H, NH2), 5.34 (d,
JH,H = 6.0 Hz, 1H, OH), 4.56 (pt, JH,H = 1.8 Hz, 2H, Cp), 4.26 (m, 2H, CH2), 4.16 (m, 1H, CH), 4.00 (bs,
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2H, Cp), 2.17 (m, 1H, CH2), 2.01 (m, 1H, CH2). 13C-NMR (150 MHz, DMSO-d6): δ = 228.0, 164.0, 153.7,
153.0, 150.0, 137.1 (d, JP,C = 40 Hz), 132.8 (d, JP,C = 20 Hz), 131.9 (d, JP,C = 11 Hz), 129.2, 128.6, 128.4 (d,
JP,C = 8 Hz), 127.9 (d, JP,C = 11 Hz), 106.0, 95.8, 83.2, 82.5, 80.5, 79.3, 63.8, 37.1. 31P{1H} NMR (243 MHz,
DMSO-d6): δ = 91.67. MS (EI, 70 eV): m/z = 629 (M+), 555(M+ − 2CO − H2O). FTIR (KBr): ≈3500
(OH), 2958, 2927, 1929 (CO), 1860 (CO), 1635 (NH), 1591 (NH) cm−1. Anal. Calcd for C33H29N5O3PMn:
C, 62.96%; H, 4.64%; N, 11.12%. Found: C, 62.71%; H, 4.88%; N, 11.04%.
Synthesis of Compound 4. Solid NaH (24 mg, 1.0 mmol) was added to a stirred solution of alcohol
2 (195 mg, 0.5 mmol) in DMF (20 mL) at ambient temperature. After stirring for 5 min, methyl
iodide (62 µL, 142 mg, 1.0 mmol) was added in one portion at ambient temperature. After 20 min of
stirring, the reaction mixture was poured into 25 mL of water, extracted with chloroform, dried over
MgSO4, and the obtained solution was evaporated to dryness. The residue was subjected to column
chromatography on SiO2 (eluent chloroform). Chromatography gave the analytically pure product 4.
4 Yellow oil, 40% (84 mg). 1H-NMR (600 MHz, DMSO-d6): δ = 8.12 (d, JH,F = 6.0 Hz, 1H, H-6
5-fluorouracil), 5.18 (s, 1H, Cp), 5.12 (s, 1H, Cp), 4.95 (s, 1H, Cp), 4.91 (s, 1H, Cp), 3.92 (t, JH,H = 6.0 Hz,
1H, CH), 3.80 (q, JH,H = 6.0 Hz, 2H, CH2), 3.17 (s, 3H, CH3), 2.00 (q, JH,H = 6.0 Hz, 2H, CH2). 1H-NMR
(600 MHz, after D2O addition, DMSO-d6 ): δ = 8.10 (bs, 1H, H-6 5-fluorouracil), 5.16 (s, 1H, Cp), 5.11 (s,
1H, Cp), 4.94 (s, 1H, Cp), 4.90 (s, 1H, Cp), 3.91 (s, 1H, CH), .79 (bs, 2H, CH2), 3.28 (s, 3H, OCH3), 3.16
(s, 3H, NCH3), 1.98 (bs, 2H, CH2). 13C-NMR (150 MHz, DMSO-d6): δ = 224.9, 156.5 (d, JC,F = 25 Hz),
149.3, 138.7 (d, JC,F = 225 Hz), 128.4 (d, JC,F = 34 Hz), 104.8, 83.7, 83.2, 82.1, 81.6, 73.5, 56.1, 45.6, 33.6,
27.6. MS (EI, 70 eV): m/z = 418 (M+), 334 (M+ − 3CO), 302 (M+ − 3CO − CH3OH). FTIR (KBr): 2021
(CO), 1923 (CO), 1711 (C=O), 1679 (C=O), 1651 (C=O) cm−1. Anal. Calcd for C17H16N2O6FMn + H2O:
C, 46.80%; H, 4.16%. Found: C, 46.86%; H, 4.25%.
Synthesis of Compound 6. Solid NaH (36 mg, 1.5 mmol) was added to a stirred solution of alcohol B
(198 mg, 0.5 mmol) in DMF (20 mL) at ambient temperature. After stirring for 2 h, methyl iodide (93 µL,
213 mg, 1.5 mmol) was added in one portion at ambient temperature. After 4 h of stirring, the reaction
mixture was poured into 25 mL of water, extracted with chloroform, dried over MgSO4, and the
obtained solution was evaporated to dryness. The residue was subjected to column chromatography
on SiO2 (eluent chloroform). Crystallization from chloroform/n-pentane gave the analytically pure
compound 6.
6 Colorless solid, 79% (173 mg). 1H-NMR (600 MHz, DMSO-d6): δ = 8.20 (s, 1H, H-2 adenine), 8.13 (s,
1H, H-8 adenine), 5.22 (m, 1H, Cp), 5.13 (m, 1H, Cp), 4.93 (pq, JH,H = 2.4 Hz, JH,H = 1.8 Hz, 1H, Cp), 4.90
(pq, JH,H = 2.4 Hz, JH,H = 1.8 Hz, 1H, Cp), 4.25 (m, 2H, CH2), 3.80 (dd, JH,H = 8.7 Hz, JH,H = 3.6 Hz, 1H,
CH), 3.44 (bs, 6H, N(CH3)2), 2.21 (m, 2H, CH2). 1H-NMR (600 MHz, after D2O addition, DMSO-d6):
δ = 8.18 (s, 1H, H-2 adenine), 8.11 (s, 1H, H-8 adenine), 5.18 (s, 1H, Cp), 5.09 (s, 1H, Cp), 4.90 (s, 1H, Cp),
4.87 (s, 1H, Cp), 4.24 (m, 2H, CH2), 3.77 (dd, JH,H = 8.4 Hz, JH,H = 3.6 Hz, 1H, CH), 3.50 (bs, 6H, N(CH3)2
adenine), 3.27 (s, 3H, OCH3), 2.18 (m, 2H, CH2). 13C-NMR (150 MHz, DMSO-d6): δ = 225.3, 154.3,
151.7, 150.4, 139.7, 119.3, 104.8, 84.3, 83.8, 82.4, 81.9, 73.7, 56.6, 35.3. MS (EI, 70 eV): m/z = 437 (M+),
422 (M+ − CH3), 353 (M+ − 3CO) FTIR (KBr): 3072 (CH), 3037 (CH), 2927 (CH), 2819 (CH), 2018 (CO),
1929 (CO), 1600, 1568 cm−1. Anal. Calcd for C19H20N5O4Mn: C, 52.18%; H, 4.61%; N, 16.01%. Found:
C, 52.23%; H, 4.68%; N, 16.19%.
Synthesis of Compound 7. To a stirred solution of cymantrene (204 mg, 1.0 mmol) in dichloromethane
(20 mL), propionylchloride (88 µL, 1 mmol) and AlCl3 (133 mg, 1.0 mmol) was added. After 4 h
at ambient temperature, the reaction mixture was poured into a 3% aqueous HCl solution.
Resulting dichloromethane and water phases were separated. The dichloromethane phase was
dried over MgSO4 and evaporated to dryness. The residue was dissolved in dichloromethane and
was subjected to column chromatography on SiO2 (eluent dichloromethane) to give compound 7.
Crystallization from dichloromethane/n-pentane afforded the analytically pure 7.
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7 Yellow solid, 71% (184 mg). 1H-NMR (600 MHz, DMSO-d6): δ = 5.77 (pt, JH,H = 2.4 Hz, 2H, Cp),
5.19 (pt, JH,H = 2.4 Hz, 2H, Cp), 2.66 (q, JH,H = 7.2 Hz, 2H, CH2), 1.02 (t, JH,H = 7.2 Hz, 3H, CH3).
13C-NMR (150 MHz, DMSO-d6): δ = 223.8, 198.3, 92.2, 87.4, 85.2, 31.8, 8.1. MS (EI, 70 eV): m/z = 260
(M+). FTIR (KBr): 3091 (CH), 2987 (CH), 2842 (CH), 2908 (CH), 2027 (CO), 1942 (CO), 1676 (C=O) cm−1.
Anal. Calcd for C11H9O4Mn: C, 50.79%; H, 3.49%. Found: C, 50.90%; H, 3.64%.
4.3. Single-Crystal X-ray Structure Analysis of 1, 6 and C
Good quality single-crystals of 1, 6 and C were selected for the X-ray diffraction experiments
at T = 100(2) K. Diffraction data were collected on the Agilent Technologies SuperNova Dual Source
diffractometer (Yarnton, UK) with CuKα radiation (λ = 1.54184 Å) using CrysAlis RED software
(CrysAlis CCD and CrysAlis RED, Oxford Diffraction, Oxford Diffraction Ltd.: Yarnton, UK, 2008) [61].
In all cases, the analytical numerical absorption correction was applied [61] using a multifaceted crystal
model based on expressions that were derived by Clark and Reid (1994) [62], as implemented in the
SCALE3 ABSPACK scaling algoritm [61]. The structural determination procedure was carried out
using the SHELX package [63]. The structures were solved by direct methods and then successive
least-square refinement was carried out based on the full-matrix least-squares method on F2 using the
SHELXL program [63]. All of the H-atoms bound to C-atoms were positioned geometrically, with C–H
equal to 0.93, 0.96, 0.97 and 0.98 Å for aromatic, methyl, methylene and methine H-atoms, respectively,
and were constrained to ride on their parent atoms with Uiso(H) = xUeq(C), where x = 1.2 for the
aromatic, methylene and H-atoms, and x = 1.5 for the methyl H-atoms. The H-atoms that were linked
to N-atoms were located on a Fourier difference map and refined as riding with Uiso(H) = 1.2Ueq(N).
In the case of 1, a few distinct peaks on the difference Fourier map were indicating the presence of a
disordered solvent molecule. However, all of the attempts to model a disordered solvents used for
crystallization failed. Therefore, the solvent contribution was removed by applying the appropriate
MASK procedure in the Olex2 program [64]. Calculated void volume was approximately 204.7 Å3
occupied by 48.4 electrons per unit cell. The figures presented in this work were prepared using Olex2
and ORTEP-3 programs [64,65]. The molecular interactions were identified using PLATON [66].
4.4. Determination of the Log Po/w
For the determination of log Po/w values, the newly synthesized compounds were analyzed by an
Agilent 1200 system (Agilent Technologies, Santa Clara, CA, USA) equipped with a Zorbax Eclipse XDB
column (C18, 250 × 4.6 mm, Agilent Technologies) and controlled by the software ChemStation Data
Analysis. The separation was isocratic, and water/methanol (HPLC gradient grade, Sigma-Aldrich,
St. Louis, MO, USA) mixtures containing 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90 and 0.95 volume
fractions of organic modifier were used as the mobile phase. The flow rate was 1.0 mL/min for the 7
and 2 and 0.8 mL/min for other compounds. The chromatographic peaks of test compounds were
detected by UV absorbance at 230 nm. The column temperature was kept at 20 ◦C. The dead-time
values were measured from the effluent peaks. All of the runs were performed in triplicate, and the
resulting average values were used for the calculation of the retention factors.
4.5. Biology
4.5.1. Anticancer Activity
Cell Lines
Anticancer activity of cymantrene derivetives were determined on the basis of their cytotoxic
effects on a panel of human cancer cells, as derived from different types of solid tumors: estrogen
responsive breast adenocarcinoma (MCF-7), triple negative breast adenocarcinoma (MDA-MB-231),
ovarian adenocarcinoma (SKOV-3), non-small cell lung carcinoma (A549), hepatocellular carcinoma
(HepG2), and glioblastoma (U-87 MG). Additionally, doxorubicin resistant breast adenocarcinoma cells
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(MCF-7/Dox) were also included for comparison. All of the cell lines were purchased from American
Type Culture Collection (ATCC, Rockville, MD, USA), except the MCF-7/dox cell line, which was
a generous gift from Professor Malgorzata Latocha from the Department of Cell Biology, Medical
University of Silesia in Katowice, Poland.
Cell Culture
Cells were grown as a monolayer in DMEM growth medium, supplemented with 10% FBS,
penicillin (10 U/mL) and streptomycin (50 µg/mL), under standard conditions (37 ◦C, 5% CO2 and
95% air, 100% humidity) and periodically checked for Mycoplasma contamination.
Cytotoxicity Assay
The cytotoxicity of cymantrene derivatives was evaluated by the MTT microplate methods as
described elsewhere [67] by incubating the cells with increasing concentrations of tested compounds
for 24 h. Briefly, 0.1 mL of logarithmically growing cells were seeded in a 96-well microplate
(5× 104 cells/well) a day before the experiments and after 24 h of culture, tested compounds, dissolved
in DMSO, and diluted in culture medium, were added. The final concentration of DMSO did not
exceed 0.1%. After further incubation for 24 h, the medium was replaced with fresh medium and the
cells were allowed to grow for additional 48 h. Then, the medium was aspirated and 0.05 mL of MTT
(final concentration of 5 mg/mL medium) added to each well, and the cells were incubated for further
4 h. The absorbance of the product, resulting from the MTT reduction, was read with a microplate
reader at 545 nm. The percentage of viable cells was calculated by comparing the absorbance of
treated cells with that of the untreated control cells (taken as 100%). The IC50 concentration of each
compound was calculated from the cell survival curves using GraphPad Prism 4.02 software for
Windows (GraphPad Software, San Diego, CA, USA).
Determination of Autophagy and Apoptotic/Necrotic Cell Death
One day prior to the experiments, cells were seeded at the appropriate density into 35 mm
diameter dishes. The next day, test compounds were added at three different concentrations: 0.5× IC50,
1 × IC50, and 2 × IC50 (the final concentration of DMSO in the medium did not exceed 0.1%) and
the cells were incubated with the compounds for 24 h. At the end of incubation, the medium was
aspirated, the cell monolayer was washed twice with pre-warmed PBS, and fresh medium was added.
The cells were cultured in drug-free medium for an additional 24 or 48 h to enable them to recover
after the exposure to the compounds and to repair any induced damages.
Quantitative analysis of morphological changes that are associated with apoptosis, necrosis,
and autophagy were assessed using a fluorescence microscope (Olympus IX70, Tokyo, Japan) at
400× magnification, as described elsewhere [67]. At the indicated time points, cells were washed
with PBS, trypsinized, and centrifuged at 1000 rpm (fixed angle rotor, 72× g) for 5 min at 37 ◦C.
The supernatant was removed and the cell pellet (100 µL) was transferred to the Eppendorf tube,
mixed with Ho33258 (2 µL, 0.13 mM) and PI (2 µL, 0.23 mM), and incubated for 5 min in the
dark at room temperature. At least 300 stained cells were counted in triplicate in each of the three
independent experiments. Cells were classified as live, apoptotic, or necrotic on the basis of their
morphological and staining characteristics, and each fraction was related to the total cell number.
Double staining with these fluorescence dyes enables the identification of the status of any cell: live
cells with uniformly pale-blue fluorescent nuclei; early apoptotic cells with intact membranes but
condensed and fragmented chromatin giving rise to an intense bright-blue fluorescence of the nuclei;
late-apoptotic cells with blue-violet fluorescence due to condensed and fragmented chromatin and
permeabilized plasma membranes allowing for small amounts of PI to enter the cells; and, swollen
necrotic cells with damaged plasma membranes giving rise to red fluorescence caused by PI.
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The ability of tested compounds to induce autophagosome formation inside cells (the process
associated with the induction of autophagy) was evaluated by microscopic examination of the
morphology of cells stained with acridine orange (AO).
Determination of Intracellular ROS
The intracellular ROS were measured with the oxidation-sensitive fluorescent probes
2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) (Sigma-Aldrich, St. Louis, MO, USA), as
described elsewhere [68]. The cell-permeant non-fluorescent dye H2DCF-DA is a reduced form of
fluorescein that inside the cell, upon cleavage of the acetate groups by intracellular esterases and
oxidation by ROS, is converted into the highly fluorescent product 2′,7′-dichlorofluorescein (DCF)
(λex/λem: 498/525 nm). For the assay, 2 × 104 cells were seeded into wells of black flat-bottom
96-well microplates a day before the experiment. The next day, test compounds were added at
concentrations of 0.5 × IC50, 1 × IC50, and 2 × IC50. The final concentration of DMSO did not exceed
0.1%. After 24 h incubation, medium was removed, cell monolayers were washed twice with HBSS
and 5 µM H2DCF-DA, dissolved in HBSS, was added to each well. The cells were incubated with the
fluorescent probe for 30 min in the dark at 37 ◦C, and then the fluorescence of produced DCF was
monitored over a time period of 0–3 h at 15-min intervals with a microplate reader.
4.5.2. Statistical Analysis
All data are expressed as a mean ± SD. An ANOVA analysis of variance with a Tuckey post hoc
test were used for multiple comparisons. A statistical program STATISTICA (StatSoft, Tulsa, OK, USA)
was used for all statistical calculations. A p value of <0.05 was considered significant.
4.5.3. Trypanocidal Assay
Bloodstream forms of T. brucei clone 427-221a [69] and human myeloid leukemia HL-60 cells [56]
were grown in Baltz medium [70] and were supplemented with 16.7% heat-inactivated fetal calf
serum. All of the cultures were maintained at 37 ◦C in a humidified atmosphere containing 5% of
CO2. Toxicity assays were performed, as previously described, with some modifications [71]. In brief,
trypanosomes and HL-60 cells were seeded at an initial cell density of 104/mL and 5 × 104/mL,
respectively, in 96-well plates in a final volume of 200 µL culture medium containing various
concentrations of test compounds dissolved in 100% DMSO. It should be noted that none of the
test compounds formed precipitates when diluted with medium. The controls contained DMSO alone.
In all of the experiments, the final DMSO concentration was 0.9%. After 24 h incubation, 20 µL of a
0.5 mM resazurin solution prepared in PBS was added and the cultures were incubated for a further
48 h. Resazurin is a vital dye that, when being reduced by living cells, changes its colour from blue to
pink. Thus, by measuring absorbance, the proliferation of cells can be easily determined. The change
in absorbance was read with a microplate reader using a test wavelength of 570 nm and a reference
wavelength of 630 nm. GI50 values were calculated by linear interpolation according to the method
described by Huber and Koella [72]. MIC values were determined microscopically.
4.5.4. Microbiology
The antibacterial activity of CymH, 1–7 and C and the reference drugs penicillin G and polymyxin
B was tested by the liquid microdilution method under standard conditions using twofold dilution
series, as described in the Clinical and Laboratory Standards Institute (CLSI), reference method M07-A8,
and expressed as minimal inhibitory concentration (MIC) values [73]. A panel of Gram-positive
bacterial strains, S. aureus ATCC® 29213 (sensitive to methicillin, (MSSA)), S. aureus ATCC® 43300
(resistant to methicillin, (MRSA)), S. aureus ATCC 700787™ (intermediate to vancomycin, (VISA)), and
S. epidermidis ATCC 12228™, and one Gram-negative, strain E. coli ATCC BAA-198™ (ESBL) were used.
In addition, four clinical isolates of S. aureus (MSSA and MRSA) and two clinical isolates of S. epidermidis
that were collected from different patients at the Medical University of Warsaw, Poland, were also
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tested. The bacterial cells were cultivated on tryptic soy agar (TSA) and nutrient agar (NA), according to
ATCC recommendations. All of the strains were incubated at 37 ◦C. Tested compounds were dissolved
in DMSO and then serially diluted twofold with cation-adjusted Mueller-Hinton broth (CAMHB).
Then, 95 µL of the dilutions were dispensed into microdilution sterile plates (Mar-Four), followed by
the addition of 5 µL of bacteria inoculum containing 5 × 104 CFU/mL. The final concentrations of
the compounds ranged from 512 to 2 µg/mL. Each compound was tested in triplicate, and Penicillin
G (8–0.15 µg/mL) and Polymyxin B (256–0.0625 µg/mL) were used as controls. The plates were
incubated at 37 ◦C for 18 to 24 h depending on the bacterial strain. Thereafter, the absorbance was
measured at λ = 540 nm and λ = 595 nm using a Spectrostar Omega microplate reader (BMG Labtech,
Offenburg, Germany). The MIC value was defined as the lowest concentration of a compound that
reduced the growth by 100%.
The effect of compound 1 on bacterial morphology was studied by SEM, as previously
described [74]. Briefly, samples of S. aureus ATCC 25923 (105 CFU/mL) were centrifuged (600× g, 5 min)
and resuspended in growth medium containing compound 1 at concentration of 48 or 64 µg/mL.
After incubation for 24 h at 37 ◦C, the cells were washed twice with PBS (0.1 × PBS), fixed with 2.5%
glutaraldehyde (overnight), filtered (0.2 µm, pore size cutoff), and subsequently dehydrated in a
series of ethanol washes (30%, 50%, 70%, 80%, 90% and 100%; twice for 15 min). The solvent was
then evaporated and the samples were coated with a thin layer of platinum (15 nm). SEM images
were recorded using a SEM Inspect F50 (FEI Co., Eindhoven, The Netherlands) at an energy range
of 10–15 keV.
4.5.5. Deposited Data
Cif files of the structure determinations were deposited at the Cambridge Crystallographic Data
Center (CCDC numbers 1575005-1575007). These data can be obtained free of charge via www.ccdc.
cam.ac.uk/structures.
5. Conclusions
This study indicates that cymantrene derivatives display biological activities against a variety
of different cell types. In addition to recently published results on the trypanocidal activity of
cymantrene compounds, here we show that some of these organometallics also exhibit anticancer
and antibacterial activities. Evidence was provided that cytotoxic and antiproliferative properities
of investigated cymantrene derivatives toward human cancer cells could stem from the abilities of
these compounds to induce apoptosis, autophagy, and oxidative stress, which could be considered
as possible mechanisms of anticancer activity of cymantrenes. This assumption, however, needs
further more detailed studies. The most prominent feature of biological activity of investigated
cymantrene derivatives is their selective anticancer activity toward cancer cells that were derived from
triple negative breast adenocarcinoma (MDA-MB-231), doxorubicin-resistant hormone-dependent
breast adenocarcinoma (MCF-7/DOX), ovarian adenocarcinoma (SCOV-3), and non-small lung cell
adenocarcinoma (A549), cancers refractory to conventional chemotherapy.
In bacteria, cymantrenes seemed to cause shrinking of cells, although it remains uncertain
whether this process was a direct effect of the cymantrene derivatives or whether the compounds
that prevented the growth of the cells and the observed smaller cell size was the result of ongoing
cell division. Another important finding of the study is that cymantrene compounds containing a
triphenylphosphine ligand displayed generally higher biological activity.
Supplementary Materials: Supplementary materials are available online.
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